<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03234036</url>
  </required_header>
  <id_info>
    <org_study_id>205820</org_study_id>
    <nct_id>NCT03234036</nct_id>
  </id_info>
  <brief_title>A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir</brief_title>
  <official_title>A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in two Parts to confirm the acceptability/selection of a tablet&#xD;
      formulation for future clinical development of GSK2838232. Part 1 of the study will assess&#xD;
      single ritonavir (RTV)-boosted doses of a new tablet formulation given with food (containing&#xD;
      approximately 30% fat) against the reference capsule formulation also given with food and&#xD;
      then will assess the impact of fasted conditions on the tablet performance. In Part 2,&#xD;
      non-boosted GSK2838232 will be given as once-daily tablet doses for 11 days in a separate&#xD;
      group of subjects, assuming the tablet performance is considered acceptable from Part 1.&#xD;
      Approximately 16 healthy subjects will be enrolled to provide at least 12 evaluable subjects&#xD;
      through the three study periods in Part 1. 10 healthy subjects will be enrolled to provide at&#xD;
      least 8 evaluable subjects through the single study period in Part 2. The maximum duration of&#xD;
      study participation will be approximately 9 to 10 weeks for Part 1; and 8 to 9 weeks for Part&#xD;
      2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The randomization number will determine the allocation of treatment sequences (ABC or BAC) for Part 1, and of treatment (GSK2838232 without RTV or placebo) for Part 2. Allocation to treatment for Part 1A or Part 1B (with Part 2 being fixed) will be according to a predetermined random order.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part 1 of the study will be open label and thus not be blinded. Part 2 of the study will be single blinded because of the unavailability of matching placebo tablets. The Principal Investigator and the subject will be completely blinded to specific treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable [NQ] values were considered as non-missing values).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Safety Population comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt; 0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt; 3 or &gt;20 cells per liter (cells/L) for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times Upper limit of Normal (ULN) units per liter (U/L) for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN micromoles per liter (µmol/L) for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</measure>
    <time_frame>Up to 25 days</time_frame>
    <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, potential of hydrogen (pH), presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Blood Pressure at Indicated Time Points</measure>
    <time_frame>Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
    <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in supine position after 10 minutes rest for the participants at indicated time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
    <description>SBP and DBP were measured in supine position after 10 minutes rest for participants at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Pulse Rate at Indicated Time Points</measure>
    <time_frame>Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
    <description>Pulse rate of participants was measured in supine position after 10 minutes rest at indicated time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
    <description>Pulse rate was measured in supine position after 10 minutes rest at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day -1; 1, 4, 12 hours on Day 1; Days 2, 3, 5, 8; 1, 4, 12, 24 Hours on Day 11; Follow-up (Day 25)</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in Mean Heart Rate Values as ECG Parameter</measure>
    <time_frame>Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</measure>
    <time_frame>Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With SAEs and Non-SAEs</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &gt;0.54 as proportion of red blood cells in blood for hematocrit, &gt;180 g/L for hemoglobin, &lt; 3 or &gt;20 cells/L for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or 2.75 mmol/L for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times ULN U/L for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN µmol/L for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, pH, presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Blood Pressure at Indicated Time Points</measure>
    <time_frame>Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
    <description>SBP and DBP of participants were measured in supine position after 10 minutes rest at indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
    <description>SBP and DBP were measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Pulse Rate at Indicated Time Points</measure>
    <time_frame>Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
    <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
    <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Abnormal ECG Findings</measure>
    <time_frame>Day -2, Day -1; 1, 2, 4, 6, 8, , 12, 24, 48, 72 hours on Day 1</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTcF intervals. CS and NCS abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Mean Heart Rate Values as ECG Parameter</measure>
    <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</measure>
    <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1</time_frame>
    <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tlag Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tmax Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: T1/2 Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Tlast Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Plasma Drug Concentration at 24 Hours (C24) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC(0-t) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State</measure>
    <time_frame>Pre-dose on Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10 and Day 11 in Part 2</time_frame>
    <description>Blood sample were collected at indicated time points to assess pre-dose concentration of GSK2838232 when administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2. Slope and 90 percent confidence interval have been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood sample were collected at indicated time points to calculate accumulation ratio from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, AUC (0-tau) divided by Day 1, AUC (0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Cmax divided by Day 1, Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</measure>
    <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
    <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Ctau divided by Day 1, Ctau.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.&#xD;
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.&#xD;
Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.&#xD;
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.&#xD;
There will be a wash out of 15 days between Part 1A and Part 1B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.&#xD;
A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.&#xD;
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.&#xD;
There will be a wash out of 15 days between Part 1A and Part 1B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2838232 tablet without RTV: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo without RTV: Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2838232 100 mg tablet</intervention_name>
    <description>It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.</description>
    <arm_group_label>GSK2838232 tablet without RTV: Part 2</arm_group_label>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2838232 50 mg capsule</intervention_name>
    <description>It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.</description>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 mg tablets</intervention_name>
    <description>It is a white film-coated ovaloid tablets.</description>
    <arm_group_label>Treatment sequence ABC: Part 1</arm_group_label>
    <arm_group_label>Treatment sequence BAC: Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for GSK2838232 tablets</intervention_name>
    <description>It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.</description>
    <arm_group_label>Placebo without RTV: Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.&#xD;
&#xD;
          -  Healthy as determined by the Investigator or medically qualified designee based on a&#xD;
             medical evaluation including medical history, physical examination, laboratory tests&#xD;
             and cardiac monitoring.&#xD;
&#xD;
          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not&#xD;
             specifically listed in the inclusion or exclusion criteria, and outside the reference&#xD;
             range for the population being studied, may be included only if the Investigator in&#xD;
             consultation with the medical monitor, if required, agree and document that the&#xD;
             finding is unlikely to introduce additional risk factors and will not interfere with&#xD;
             the study procedures.&#xD;
&#xD;
          -  A creatinine clearance (CLcr) &gt; 80 milliliter per minute (mL/min) as determined by&#xD;
             Cockcroft-Gault equation: CLcr = (140 minus age) multiplied by weight divided by (72&#xD;
             multiplied by serum creatinine) (times 0.85 if female) where age is in years, weight&#xD;
             in kilogram (kg), and serum creatinine is in units of milligram per deciliter (mg/dL).&#xD;
&#xD;
          -  Body weight &gt;=50.0 kg (110 pounds [lbs.]) for men and &gt;=45.0 kg (99 lbs) for women and&#xD;
             body mass index (BMI) within the range 18.5 to 31.0 kg/meter (m)^2 (inclusive).&#xD;
&#xD;
          -  Males or females.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is not pregnant (as confirmed by a&#xD;
             negative serum human chorionic gonadotrophin [hCG] test), not lactating, and of&#xD;
             non-reproductive potential which is defined as:&#xD;
&#xD;
        Reproductive potential:&#xD;
&#xD;
        There is no definitive drug-drug interaction (DDI) information with GSK2838232 and an&#xD;
        interaction with oral contraceptives is possible, so other (barrier, inter-uterine device&#xD;
        etc.) methods of contraception will be required. Females of reproductive potential may only&#xD;
        be enrolled if they are using two forms of complementary contraception, which must include&#xD;
        at least one barrier method. They will be counseled on safer sex practices. Fertile&#xD;
        females, who have an established, long-term lifestyle of sexual abstinence, or only same&#xD;
        sex partners, require no other means of birth control.&#xD;
&#xD;
        Non-reproductive potential:&#xD;
&#xD;
          -  Pre-menopausal females with one of the following: Documented tubal ligation;&#xD;
             documented hysteroscopic tubal occlusion procedure with follow-up confirmation of&#xD;
             bilateral tubal occlusion; hysterectomy; documented Bilateral Oophorectomy.&#xD;
&#xD;
          -  Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels&#xD;
             consistent with menopause. Females on hormone replacement therapy (HRT) must&#xD;
             discontinue HRT to allow confirmation of post-menopausal status prior to study&#xD;
             enrolment.&#xD;
&#xD;
               -  Male subjects with female partners of child bearing potential must comply with&#xD;
                  the following contraception requirements from the time of first dose of study&#xD;
                  medication until one week after the last dose of study medication.&#xD;
&#xD;
          -  Vasectomy with documentation of azoospermia.&#xD;
&#xD;
          -  Male condom plus partner use of one of the contraceptive options below: Contraceptive&#xD;
             subdermal implant with a &lt;1 percent rate of failure per year; intrauterine device or&#xD;
             intrauterine system with a &lt;1 percent rate of failure per year; oral contraceptive,&#xD;
             either combined or progestogen alone or injectable progestogen; contraceptive vaginal&#xD;
             ring; percutaneous contraceptive patches.&#xD;
&#xD;
               -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALT &gt;1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35 percent).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary&#xD;
             abnormalities.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma.&#xD;
&#xD;
          -  Medical history of cardiac arrhythmias or cardiac disease or a family or personal&#xD;
             history of long QT syndrome.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GlaxoSmithKline medical monitor, the medication will not interfere&#xD;
             with the study procedures or compromise participant safety.&#xD;
&#xD;
          -  History of regular alcohol consumption (within 6 months prior to screening or unable&#xD;
             to refrain from alcohol use from 5 days prior to admission through the last blood&#xD;
             sample collected) defined as:&#xD;
&#xD;
             • For United States sites: an average weekly intake of &gt;14 drinks for males or &gt;7&#xD;
             drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mL)&#xD;
             of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled&#xD;
             spirits.&#xD;
&#xD;
          -  Regular use of tobacco- or nicotine- containing products within 6 months prior to&#xD;
             screening. Unable to refrain from smoking from the Screening Visit through the last&#xD;
             blood sample collected. As confirmed by a urine cotinine test.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or medical&#xD;
             monitor, contraindicates their participation.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus (HCV)&#xD;
             test result at screening or within 3 months prior to first dose of study treatment.&#xD;
&#xD;
          -  Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (&gt;0.045&#xD;
             nanogram [ng]/mL by the Dimension Vista cTnI assay) for a given assay.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within 56 days.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Exclusion Criteria for 24-hour Screening Holter:&#xD;
&#xD;
               -  Any symptomatic arrhythmia (except isolated extra systoles).&#xD;
&#xD;
               -  Sustained cardiac arrhythmias (such as atrial fibrillation or flutter,&#xD;
                  supraventricular tachycardia (&gt;= 10 consecutive beats), complete heart block).&#xD;
&#xD;
               -  Non-sustained or sustained ventricular tachycardia (defined as &gt;=3 consecutive&#xD;
                  ventricular ectopic beats).&#xD;
&#xD;
               -  Any conduction abnormality (including but not specific to left or right&#xD;
                  incomplete or complete bundle branch block, atrioventricular (AV) block [2nd&#xD;
                  degree or higher], Wolff Parkinson White (WPW) syndrome etc.).&#xD;
&#xD;
               -  Sinus Pauses &gt;3 seconds.&#xD;
&#xD;
               -  300 or more supraventricular ectopic beats in 24 hours.&#xD;
&#xD;
               -  250 or more ventricular ectopic beats in 24 hours.&#xD;
&#xD;
          -  Any clinically significant abnormal echocardiogram finding.&#xD;
&#xD;
          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility&#xD;
             determination):&#xD;
&#xD;
               -  Heart rate &lt;45 or &gt;100 beats per minute (bpm) for males; &lt;50 or &gt;100 bpm for&#xD;
                  females&#xD;
&#xD;
               -  PR interval &lt;120 or &gt;220 milliseconds (msec)&#xD;
&#xD;
               -  QRS duration &lt;70 or &gt;120 msec&#xD;
&#xD;
               -  QTc interval (Fridericia's) &gt;450 msec&#xD;
&#xD;
               -  Evidence of previous myocardial infarction (does not include ST segment changes&#xD;
                  associated with re-polarization).&#xD;
&#xD;
               -  Any conduction abnormality (including but not specific to left or right complete&#xD;
                  bundle branch block, AV block [2nd degree or higher], WPW syndrome).&#xD;
&#xD;
               -  Sinus Pauses &gt;3 seconds.&#xD;
&#xD;
               -  Any significant arrhythmia which, in the opinion of the Investigator or GSK&#xD;
                  medical monitor, will interfere with the safety for the individual subject.&#xD;
&#xD;
               -  Non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular&#xD;
                  ectopic beats).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson M, Jewell RC, Gan J, Dumont E, Burns O, Johns BA. A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses. Clin Pharmacol Drug Dev. 2020 Nov;9(8):972-977. doi: 10.1002/cpdd.820. Epub 2020 Jun 18.</citation>
    <PMID>32558338</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <results_first_submitted>November 8, 2018</results_first_submitted>
  <results_first_submitted_qc>November 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2019</results_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2838232</keyword>
  <keyword>safety</keyword>
  <keyword>food effect</keyword>
  <keyword>capsule</keyword>
  <keyword>healthy</keyword>
  <keyword>PK</keyword>
  <keyword>tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>GSK-2838232</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study is available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20589</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03234036/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03234036/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This two-part study assessed the relative bioavailability and food effect of a novel tablet formulation of boosted-GSK2838232 compared to capsule along with safety and pharmacokinetics of repeated once-daily doses of non-boosted GSK2838232. This study was conducted at a single center in the United States.</recruitment_details>
      <pre_assignment_details>Participants received GSK2838232 200 milligrams (mg)/ritonavir as capsule or tablet formulation in Part 1 and GSK2838232 500 mg or placebo in Part 2. A total number of 16 participants were enrolled in Part 1 of the study and 10 participants were enrolled in Part 2. In total, 26 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2838232 Capsule Fed/Tablet Fed/Tablet Fasted With Ritonavir</title>
          <description>Eligible participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.</description>
        </group>
        <group group_id="P2">
          <title>GSK2838232 Tablet Fed/Capsule Fed/Tablet Fasted With Ritonavir</title>
          <description>Eligible participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fed conditions in treatment period 1 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule administered under fed conditions in treatment period 2 along with ritonavir 100 mg tablet to be taken with water in fed condition, followed by a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition. Treatment period 1 and 2 were separated by a wash-out period of 10 days. Treatment period 2 and 3 were separated by 15 days wash-out period.</description>
        </group>
        <group group_id="P3">
          <title>Part 2: Placebo</title>
          <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
        </group>
        <group group_id="P4">
          <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
          <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1: Treatment Period 1(Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1:Washout Period 1 (Up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1: Treatment Period 2(Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1:Washout Period 2 (Up to 15 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1:Treatment Period 3 (Up to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 (Up to 25 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: All Participants Receiving GSK2838232/Ritonavir</title>
          <description>Eligible participants were assigned to treatment sequence AB or BA where A=single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule under fed condition and B=single dose of GSK2838232 200 mg (as 4 x 50 mg) tablet formulations administered under fed condition in treatment periods 1 and 2 along with ritonavir 100 mg to be taken with water in fed condition. Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet administered under fasted conditions in treatment period 3 along with ritonavir 100 mg to be taken with water in fasted condition. Treatment periods 1 and 2 were separated by a wash-out period of 10 days. Treatment periods 2 and 3 were separated by a wash-out period of 15 days.</description>
        </group>
        <group group_id="B2">
          <title>Part 2: Placebo</title>
          <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
        </group>
        <group group_id="B3">
          <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
          <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="9.54"/>
                    <measurement group_id="B2" value="41.0" spread="9.64"/>
                    <measurement group_id="B3" value="34.6" spread="7.81"/>
                    <measurement group_id="B4" value="36.38" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>BLACK OR AFRICAN AMERICAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MULTIPLE-ASIAN &amp; BLACK OR AFRICAN AMERICAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AMERICAN INDIAN OR ALASKA NATIVE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable [NQ] values were considered as non-missing values).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable [NQ] values were considered as non-missing values).</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4672.28" spread="40.68"/>
                    <measurement group_id="O2" value="4437.98" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.054" spread="48.01"/>
                    <measurement group_id="O2" value="118.118" spread="27.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation administered under fed conditions in treatment periods 1 and 2 along with ritonavir 100 mg tablet to be taken with water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4437.98" spread="30.83"/>
                    <measurement group_id="O2" value="1816.27" spread="36.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation administered under fed conditions in treatment periods 1 and 2 along with ritonavir 100 mg tablet to be taken with water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.118" spread="27.59"/>
                    <measurement group_id="O2" value="50.437" spread="35.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation administered under fed conditions in treatment periods 1 and 2 along with ritonavir 100 mg tablet to be taken with water in fed condition.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.983" lower_limit="2.00" upper_limit="24.03"/>
                    <measurement group_id="O2" value="3.508" lower_limit="2.00" upper_limit="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Safety Population comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Safety Population comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria</title>
        <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt; 0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt; 3 or &gt;20 cells per liter (cells/L) for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria</title>
          <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &lt; 0.075 or &gt;0.54 proportion of red blood cells in blood for hematocrit, &lt;25 or &gt;180 grams per liter (g/L) for hemoglobin, &lt; 3 or &gt;20 cells per liter (cells/L) for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</title>
        <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times Upper limit of Normal (ULN) units per liter (U/L) for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN micromoles per liter (µmol/L) for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</title>
          <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times Upper limit of Normal (ULN) units per liter (U/L) for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN micromoles per liter (µmol/L) for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</title>
        <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, potential of hydrogen (pH), presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
        <time_frame>Up to 25 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</title>
          <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, potential of hydrogen (pH), presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Blood Pressure at Indicated Time Points</title>
        <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in supine position after 10 minutes rest for the participants at indicated time points.</description>
        <time_frame>Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Blood Pressure at Indicated Time Points</title>
          <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in supine position after 10 minutes rest for the participants at indicated time points.</description>
          <population>Safety Population</population>
          <units>Millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.667" spread="7.5056"/>
                    <measurement group_id="O2" value="73.143" spread="4.7759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.443" spread="2.6925"/>
                    <measurement group_id="O2" value="72.333" spread="8.1636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.667" spread="3.7859"/>
                    <measurement group_id="O2" value="64.714" spread="5.8228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.000" spread="1.0000"/>
                    <measurement group_id="O2" value="63.714" spread="6.7507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.667" spread="4.0415"/>
                    <measurement group_id="O2" value="73.714" spread="6.0474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.000" spread="1.7321"/>
                    <measurement group_id="O2" value="68.000" spread="7.3485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.000" spread="2.6458"/>
                    <measurement group_id="O2" value="65.143" spread="8.3552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.333" spread="4.9329"/>
                    <measurement group_id="O2" value="65.000" spread="7.3258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.667" spread="4.5092"/>
                    <measurement group_id="O2" value="66.143" spread="6.6690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.333" spread="3.0551"/>
                    <measurement group_id="O2" value="67.286" spread="4.8892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.000" spread="2.6458"/>
                    <measurement group_id="O2" value="69.286" spread="6.3957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.000" spread="4.0000"/>
                    <measurement group_id="O2" value="66.714" spread="5.0568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.000" spread="7.2111"/>
                    <measurement group_id="O2" value="66.571" spread="8.0593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.333" spread="5.1316"/>
                    <measurement group_id="O2" value="67.000" spread="8.0179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.667" spread="7.3711"/>
                    <measurement group_id="O2" value="66.571" spread="7.6563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.333" spread="4.5092"/>
                    <measurement group_id="O2" value="65.571" spread="8.5021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.667" spread="4.5092"/>
                    <measurement group_id="O2" value="64.714" spread="7.0643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.000" spread="5.5678"/>
                    <measurement group_id="O2" value="68.000" spread="8.9815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.333" spread="3.7859"/>
                    <measurement group_id="O2" value="65.000" spread="5.8878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.000" spread="1.0000"/>
                    <measurement group_id="O2" value="76.143" spread="10.5424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.000" spread="4.5826"/>
                    <measurement group_id="O2" value="123.000" spread="7.3258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.553" spread="4.1400"/>
                    <measurement group_id="O2" value="121.190" spread="10.8374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.333" spread="2.0817"/>
                    <measurement group_id="O2" value="113.000" spread="8.7178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.000" spread="8.1854"/>
                    <measurement group_id="O2" value="106.286" spread="9.6214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.667" spread="7.7675"/>
                    <measurement group_id="O2" value="113.286" spread="5.0568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.333" spread="2.3094"/>
                    <measurement group_id="O2" value="111.714" spread="8.7695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.333" spread="7.6376"/>
                    <measurement group_id="O2" value="109.000" spread="8.2260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.667" spread="2.3094"/>
                    <measurement group_id="O2" value="109.000" spread="3.0551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.667" spread="4.7258"/>
                    <measurement group_id="O2" value="107.857" spread="9.0079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.333" spread="1.1547"/>
                    <measurement group_id="O2" value="112.143" spread="8.6106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.667" spread="4.1633"/>
                    <measurement group_id="O2" value="109.571" spread="6.2412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.333" spread="7.2342"/>
                    <measurement group_id="O2" value="110.143" spread="8.7069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.000" spread="4.0000"/>
                    <measurement group_id="O2" value="106.714" spread="8.8828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.113" spread="3.8626"/>
                    <measurement group_id="O2" value="110.333" spread="9.7088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.000" spread="3.4641"/>
                    <measurement group_id="O2" value="111.571" spread="15.7041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.667" spread="6.0277"/>
                    <measurement group_id="O2" value="109.857" spread="8.7069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.333" spread="13.2035"/>
                    <measurement group_id="O2" value="105.143" spread="7.7337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.667" spread="8.0829"/>
                    <measurement group_id="O2" value="109.286" spread="8.8828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.333" spread="2.3094"/>
                    <measurement group_id="O2" value="110.286" spread="7.6966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.667" spread="5.8595"/>
                    <measurement group_id="O2" value="123.714" spread="10.6413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in Blood Pressure</title>
        <description>SBP and DBP were measured in supine position after 10 minutes rest for participants at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Blood Pressure</title>
          <description>SBP and DBP were measured in supine position after 10 minutes rest for participants at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.777" spread="4.6690"/>
                    <measurement group_id="O2" value="-7.619" spread="4.9086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.443" spread="3.6851"/>
                    <measurement group_id="O2" value="-8.619" spread="9.3099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.223" spread="2.5455"/>
                    <measurement group_id="O2" value="1.381" spread="5.6866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" spread="4.3485"/>
                    <measurement group_id="O2" value="-4.333" spread="8.5244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.557" spread="2.2180"/>
                    <measurement group_id="O2" value="-7.190" spread="8.9524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.110" spread="2.8366"/>
                    <measurement group_id="O2" value="-7.333" spread="10.9039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.777" spread="3.7175"/>
                    <measurement group_id="O2" value="-6.190" spread="7.8255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.110" spread="4.4381"/>
                    <measurement group_id="O2" value="-5.047" spread="8.9388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" spread="0.5095"/>
                    <measurement group_id="O2" value="-3.047" spread="9.4939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.557" spread="5.5901"/>
                    <measurement group_id="O2" value="-5.619" spread="8.5770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.443" spread="5.3488"/>
                    <measurement group_id="O2" value="-5.761" spread="10.0756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.110" spread="3.4708"/>
                    <measurement group_id="O2" value="-5.333" spread="11.3081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.777" spread="5.3385"/>
                    <measurement group_id="O2" value="-5.761" spread="12.2366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.110" spread="3.3729"/>
                    <measurement group_id="O2" value="-6.761" spread="10.3364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.223" spread="5.9279"/>
                    <measurement group_id="O2" value="-7.619" spread="10.1445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" spread="6.7022"/>
                    <measurement group_id="O2" value="-4.333" spread="9.7243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.890" spread="4.6224"/>
                    <measurement group_id="O2" value="-7.333" spread="9.2678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.557" spread="3.2015"/>
                    <measurement group_id="O2" value="3.810" spread="10.1939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.220" spread="3.0060"/>
                    <measurement group_id="O2" value="-8.190" spread="10.8776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.553" spread="5.6718"/>
                    <measurement group_id="O2" value="-14.904" spread="8.2260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.113" spread="5.8232"/>
                    <measurement group_id="O2" value="-7.904" spread="8.7636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.780" spread="1.8347"/>
                    <measurement group_id="O2" value="-9.476" spread="6.2626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.780" spread="5.4181"/>
                    <measurement group_id="O2" value="-12.190" spread="7.1567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.887" spread="3.6851"/>
                    <measurement group_id="O2" value="-12.190" spread="11.9632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.887" spread="7.0661"/>
                    <measurement group_id="O2" value="-13.333" spread="15.5386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.220" spread="3.7452"/>
                    <measurement group_id="O2" value="-9.047" spread="13.8084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.887" spread="5.1225"/>
                    <measurement group_id="O2" value="-11.619" spread="11.8726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.220" spread="6.1657"/>
                    <measurement group_id="O2" value="-11.047" spread="14.9222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.447" spread="7.8192"/>
                    <measurement group_id="O2" value="-14.476" spread="13.8688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.440" spread="4.4381"/>
                    <measurement group_id="O2" value="-10.857" spread="13.9763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.447" spread="6.6678"/>
                    <measurement group_id="O2" value="-9.619" spread="19.6856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.113" spread="2.6962"/>
                    <measurement group_id="O2" value="-11.333" spread="14.3479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.220" spread="13.2912"/>
                    <measurement group_id="O2" value="-16.047" spread="15.2791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.113" spread="12.0648"/>
                    <measurement group_id="O2" value="-11.904" spread="11.8344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.780" spread="1.8347"/>
                    <measurement group_id="O2" value="-10.904" spread="13.1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.113" spread="4.6808"/>
                    <measurement group_id="O2" value="2.524" spread="10.1553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Pulse Rate at Indicated Time Points</title>
        <description>Pulse rate of participants was measured in supine position after 10 minutes rest at indicated time points.</description>
        <time_frame>Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Pulse Rate at Indicated Time Points</title>
          <description>Pulse rate of participants was measured in supine position after 10 minutes rest at indicated time points.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.667" spread="12.4231"/>
                    <measurement group_id="O2" value="64.143" spread="11.7817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.663" spread="4.0415"/>
                    <measurement group_id="O2" value="63.714" spread="11.3991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.000" spread="8.5440"/>
                    <measurement group_id="O2" value="72.286" spread="7.5214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.667" spread="3.0551"/>
                    <measurement group_id="O2" value="66.000" spread="10.1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.667" spread="2.8868"/>
                    <measurement group_id="O2" value="58.286" spread="8.7123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.000" spread="2.6458"/>
                    <measurement group_id="O2" value="59.429" spread="7.9762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.667" spread="1.1547"/>
                    <measurement group_id="O2" value="58.286" spread="7.7613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.667" spread="2.5166"/>
                    <measurement group_id="O2" value="66.429" spread="10.3900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.333" spread="2.3094"/>
                    <measurement group_id="O2" value="59.143" spread="6.2564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.333" spread="3.7859"/>
                    <measurement group_id="O2" value="63.429" spread="11.4143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.333" spread="4.0415"/>
                    <measurement group_id="O2" value="62.000" spread="8.6795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.000" spread="2.6458"/>
                    <measurement group_id="O2" value="60.714" spread="6.9693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.667" spread="3.5119"/>
                    <measurement group_id="O2" value="60.143" spread="8.4346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.887" spread="1.3891"/>
                    <measurement group_id="O2" value="60.810" spread="9.3355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.667" spread="4.7258"/>
                    <measurement group_id="O2" value="70.143" spread="7.0102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.000" spread="5.2915"/>
                    <measurement group_id="O2" value="68.857" spread="8.4148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.667" spread="6.4291"/>
                    <measurement group_id="O2" value="64.571" spread="7.3679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.667" spread="6.5064"/>
                    <measurement group_id="O2" value="61.714" spread="4.6085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.000" spread="2.6458"/>
                    <measurement group_id="O2" value="60.857" spread="3.9340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.667" spread="8.0829"/>
                    <measurement group_id="O2" value="63.857" spread="9.4062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was measured in supine position after 10 minutes rest at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was measured in supine position after 10 minutes rest at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.337" spread="11.2398"/>
                    <measurement group_id="O2" value="8.571" spread="5.4337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.003" spread="6.6583"/>
                    <measurement group_id="O2" value="2.286" spread="9.4965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 2, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.997" spread="2.5166"/>
                    <measurement group_id="O2" value="-5.429" spread="4.4808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 3, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.663" spread="4.9329"/>
                    <measurement group_id="O2" value="-4.286" spread="5.9568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 4, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.997" spread="5.1316"/>
                    <measurement group_id="O2" value="-5.429" spread="7.0937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.997" spread="5.6862"/>
                    <measurement group_id="O2" value="2.714" spread="11.2383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.330" spread="4.3589"/>
                    <measurement group_id="O2" value="-4.571" spread="9.8771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.330" spread="1.0000"/>
                    <measurement group_id="O2" value="-0.286" spread="12.4265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.670" spread="0.0000"/>
                    <measurement group_id="O2" value="-1.714" spread="8.2357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.663" spread="4.9329"/>
                    <measurement group_id="O2" value="-3.000" spread="9.7265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="7.5056"/>
                    <measurement group_id="O2" value="-3.571" spread="10.5886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.777" spread="4.1400"/>
                    <measurement group_id="O2" value="-2.904" spread="10.5699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.003" spread="8.3865"/>
                    <measurement group_id="O2" value="6.429" spread="10.3760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.337" spread="8.5049"/>
                    <measurement group_id="O2" value="5.143" spread="10.9028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.003" spread="6.5064"/>
                    <measurement group_id="O2" value="0.857" spread="10.2185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.997" spread="9.4516"/>
                    <measurement group_id="O2" value="-2.000" spread="9.6686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.663" spread="4.0415"/>
                    <measurement group_id="O2" value="-2.857" spread="8.7974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.003" spread="11.9304"/>
                    <measurement group_id="O2" value="0.143" spread="10.7995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Day -1; 1, 4, 12 hours on Day 1; Days 2, 3, 5, 8; 1, 4, 12, 24 Hours on Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NCS: DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in Mean Heart Rate Values as ECG Parameter</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Mean Heart Rate Values as ECG Parameter</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" spread="10.1734"/>
                    <measurement group_id="O2" value="10.240" spread="5.0930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" spread="5.9287"/>
                    <measurement group_id="O2" value="1.954" spread="3.9733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.000" spread="6.8912"/>
                    <measurement group_id="O2" value="0.526" spread="5.1336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.000" spread="0.8826"/>
                    <measurement group_id="O2" value="-5.331" spread="4.8861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.333" spread="5.4902"/>
                    <measurement group_id="O2" value="-1.046" spread="4.9332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.667" spread="2.6062"/>
                    <measurement group_id="O2" value="2.669" spread="11.9804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.000" spread="1.8571"/>
                    <measurement group_id="O2" value="0.954" spread="5.8978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.333" spread="1.7670"/>
                    <measurement group_id="O2" value="-0.903" spread="6.9388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.333" spread="7.7564"/>
                    <measurement group_id="O2" value="6.383" spread="5.9634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="4.0986"/>
                    <measurement group_id="O2" value="4.811" spread="8.2683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.667" spread="3.8461"/>
                    <measurement group_id="O2" value="-0.189" spread="5.6490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.667" spread="4.8106"/>
                    <measurement group_id="O2" value="0.954" spread="4.8878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.333" spread="12.4705"/>
                    <measurement group_id="O2" value="0.669" spread="8.2733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.110" spread="2.0360"/>
                    <measurement group_id="O2" value="-3.999" spread="10.6110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.443" spread="3.7945"/>
                    <measurement group_id="O2" value="-12.284" spread="13.9800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.443" spread="11.9348"/>
                    <measurement group_id="O2" value="3.430" spread="5.7511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.890" spread="3.6695"/>
                    <measurement group_id="O2" value="3.716" spread="5.1471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="4.2847"/>
                    <measurement group_id="O2" value="4.573" spread="6.1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.223" spread="9.1999"/>
                    <measurement group_id="O2" value="2.287" spread="9.5818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.223" spread="10.8609"/>
                    <measurement group_id="O2" value="7.430" spread="11.6897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.113" spread="10.1172"/>
                    <measurement group_id="O2" value="7.620" spread="5.5483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.777" spread="7.3456"/>
                    <measurement group_id="O2" value="2.287" spread="5.2749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.110" spread="10.8418"/>
                    <measurement group_id="O2" value="-0.570" spread="9.9657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.223" spread="12.6221"/>
                    <measurement group_id="O2" value="1.716" spread="9.4661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.890" spread="10.8418"/>
                    <measurement group_id="O2" value="3.144" spread="6.0321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.443" spread="5.0039"/>
                    <measurement group_id="O2" value="2.001" spread="13.1373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.330" spread="5.2915"/>
                    <measurement group_id="O2" value="-1.713" spread="3.3072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.997" spread="4.6188"/>
                    <measurement group_id="O2" value="-1.713" spread="1.4322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.663" spread="4.6188"/>
                    <measurement group_id="O2" value="1.716" spread="3.6295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.330" spread="2.0000"/>
                    <measurement group_id="O2" value="0.287" spread="2.2711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.663" spread="3.0551"/>
                    <measurement group_id="O2" value="-4.570" spread="5.8288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.997" spread="4.1633"/>
                    <measurement group_id="O2" value="-1.999" spread="2.8532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="1.1547"/>
                    <measurement group_id="O2" value="-3.141" spread="4.1578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.107" spread="4.3393"/>
                    <measurement group_id="O2" value="-0.570" spread="1.9401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="2.3094"/>
                    <measurement group_id="O2" value="-0.856" spread="5.1594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.337" spread="1.1547"/>
                    <measurement group_id="O2" value="-2.570" spread="3.0890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.330" spread="3.4641"/>
                    <measurement group_id="O2" value="-0.856" spread="4.4676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.337" spread="1.1547"/>
                    <measurement group_id="O2" value="-0.570" spread="3.7401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.997" spread="11.0151"/>
                    <measurement group_id="O2" value="1.716" spread="1.5811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.223" spread="18.0177"/>
                    <measurement group_id="O2" value="-26.094" spread="12.8322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.557" spread="9.7159"/>
                    <measurement group_id="O2" value="-11.523" spread="11.6047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.443" spread="18.0654"/>
                    <measurement group_id="O2" value="-7.237" spread="15.5856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.777" spread="4.0741"/>
                    <measurement group_id="O2" value="0.763" spread="9.3458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.777" spread="18.7403"/>
                    <measurement group_id="O2" value="-8.951" spread="11.9189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.890" spread="8.9502"/>
                    <measurement group_id="O2" value="-10.666" spread="19.1883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.110" spread="2.3378"/>
                    <measurement group_id="O2" value="-8.951" spread="14.2945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.553" spread="6.1963"/>
                    <measurement group_id="O2" value="-4.283" spread="13.7560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.223" spread="12.2979"/>
                    <measurement group_id="O2" value="-28.380" spread="19.3087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.223" spread="10.0299"/>
                    <measurement group_id="O2" value="-20.380" spread="17.7740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.777" spread="10.5451"/>
                    <measurement group_id="O2" value="-13.237" spread="13.1751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.890" spread="12.6010"/>
                    <measurement group_id="O2" value="-13.523" spread="11.7381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.443" spread="26.9777"/>
                    <measurement group_id="O2" value="-3.237" spread="20.6284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.667" spread="6.3366"/>
                    <measurement group_id="O2" value="-5.857" spread="10.3146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="2.1838"/>
                    <measurement group_id="O2" value="-7.429" spread="7.1165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.000" spread="8.2158"/>
                    <measurement group_id="O2" value="-6.286" spread="10.9182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.667" spread="4.6671"/>
                    <measurement group_id="O2" value="-10.143" spread="6.7366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.000" spread="7.6908"/>
                    <measurement group_id="O2" value="-10.714" spread="9.6264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.667" spread="4.1800"/>
                    <measurement group_id="O2" value="-6.286" spread="7.6605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.000" spread="2.0246"/>
                    <measurement group_id="O2" value="-6.714" spread="6.5305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 11, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.887" spread="2.9150"/>
                    <measurement group_id="O2" value="-6.476" spread="5.7033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 11, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="4.8434"/>
                    <measurement group_id="O2" value="-15.286" spread="11.1814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 11, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.667" spread="6.1719"/>
                    <measurement group_id="O2" value="-11.000" spread="4.8767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 11, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.333" spread="3.8474"/>
                    <measurement group_id="O2" value="-12.571" spread="7.6845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 11, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.667" spread="2.9652"/>
                    <measurement group_id="O2" value="-10.429" spread="7.7286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; Follow-up (DAY 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" spread="5.8145"/>
                    <measurement group_id="O2" value="-2.571" spread="12.9581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="895.42" spread="39.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1184.55" spread="35.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.575" spread="45.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.239" spread="34.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.620" spread="42.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.668" spread="41.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.500" lower_limit="1.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1816.34" spread="37.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.217" spread="37.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.800" lower_limit="95.10" upper_limit="118.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With SAEs and Non-SAEs</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
        <time_frame>Up to 60 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With SAEs and Non-SAEs</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Number of participants with SAEs and common non-SAEs (&gt;=5%) are presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria</title>
        <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &gt;0.54 as proportion of red blood cells in blood for hematocrit, &gt;180 g/L for hemoglobin, &lt; 3 or &gt;20 cells/L for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
        <time_frame>Up to 60 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria</title>
          <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were &gt;0.54 as proportion of red blood cells in blood for hematocrit, &gt;180 g/L for hemoglobin, &lt; 3 or &gt;20 cells/L for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and &lt;100 or &gt;550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</title>
        <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or 2.75 mmol/L for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times ULN U/L for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN µmol/L for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
        <time_frame>Up to 60 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria</title>
          <description>Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium, potassium and sodium. PCI ranges were &lt;30 g/L for albumin, &lt;2 or 2.75 mmol/L for calcium, &lt;3 or &gt;9 mmol/L for glucose, &gt;=2 times ULN U/L for ALT, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &gt;=1.5 times ULN µmol/L for bilirubin, &lt;3 or &gt;5.5 mmol/L for potassium, and &lt;130 or &gt;150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the &quot;To within Range or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To within Range or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</title>
        <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, pH, presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
        <time_frame>Up to 60 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria</title>
          <description>Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, pH, presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the &quot;To Normal or No Change&quot; category.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood ; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific gravity To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine pH; To Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Blood Pressure at Indicated Time Points</title>
        <description>SBP and DBP of participants were measured in supine position after 10 minutes rest at indicated time points.</description>
        <time_frame>Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Blood Pressure at Indicated Time Points</title>
          <description>SBP and DBP of participants were measured in supine position after 10 minutes rest at indicated time points.</description>
          <population>Safety Population</population>
          <units>Millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; DAY -2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.667" spread="6.2981"/>
                    <measurement group_id="O2" value="69.533" spread="7.6426"/>
                    <measurement group_id="O3" value="65.000" spread="6.1893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.467" spread="6.2320"/>
                    <measurement group_id="O2" value="68.467" spread="8.7657"/>
                    <measurement group_id="O3" value="65.643" spread="7.7619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.956" spread="4.9419"/>
                    <measurement group_id="O2" value="66.245" spread="7.1653"/>
                    <measurement group_id="O3" value="66.929" spread="7.4379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.200" spread="6.1551"/>
                    <measurement group_id="O2" value="64.133" spread="6.1163"/>
                    <measurement group_id="O3" value="67.357" spread="5.4998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.133" spread="5.6552"/>
                    <measurement group_id="O2" value="62.533" spread="4.6425"/>
                    <measurement group_id="O3" value="66.071" spread="7.1410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.733" spread="6.6490"/>
                    <measurement group_id="O2" value="64.400" spread="5.3825"/>
                    <measurement group_id="O3" value="67.429" spread="5.5152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.400" spread="6.1968"/>
                    <measurement group_id="O2" value="64.067" spread="7.4878"/>
                    <measurement group_id="O3" value="66.071" spread="5.5117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.333" spread="6.6940"/>
                    <measurement group_id="O2" value="66.933" spread="5.0351"/>
                    <measurement group_id="O3" value="68.000" spread="6.1269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.867" spread="5.5532"/>
                    <measurement group_id="O2" value="67.800" spread="7.2723"/>
                    <measurement group_id="O3" value="66.214" spread="5.1766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.400" spread="6.4343"/>
                    <measurement group_id="O2" value="66.533" spread="6.2663"/>
                    <measurement group_id="O3" value="66.929" spread="7.0870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.600" spread="7.4431"/>
                    <measurement group_id="O2" value="67.333" spread="5.5377"/>
                    <measurement group_id="O3" value="64.643" spread="6.1595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.600" spread="8.0250"/>
                    <measurement group_id="O2" value="67.067" spread="5.2026"/>
                    <measurement group_id="O3" value="64.429" spread="7.1545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY -2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.667" spread="9.9115"/>
                    <measurement group_id="O2" value="109.733" spread="9.0116"/>
                    <measurement group_id="O3" value="105.786" spread="9.8775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.067" spread="10.2153"/>
                    <measurement group_id="O2" value="104.000" spread="9.7980"/>
                    <measurement group_id="O3" value="108.429" spread="11.1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.156" spread="9.2400"/>
                    <measurement group_id="O2" value="108.289" spread="11.1021"/>
                    <measurement group_id="O3" value="106.858" spread="9.5900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.000" spread="10.0428"/>
                    <measurement group_id="O2" value="108.400" spread="8.3820"/>
                    <measurement group_id="O3" value="106.500" spread="9.3377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.867" spread="10.6091"/>
                    <measurement group_id="O2" value="105.067" spread="9.6323"/>
                    <measurement group_id="O3" value="106.214" spread="11.8593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.733" spread="9.1844"/>
                    <measurement group_id="O2" value="106.000" spread="8.8237"/>
                    <measurement group_id="O3" value="106.714" spread="10.8019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.333" spread="8.9894"/>
                    <measurement group_id="O2" value="106.933" spread="7.1661"/>
                    <measurement group_id="O3" value="108.214" spread="11.8008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.067" spread="8.9639"/>
                    <measurement group_id="O2" value="110.600" spread="12.3508"/>
                    <measurement group_id="O3" value="106.000" spread="12.3973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.133" spread="10.2181"/>
                    <measurement group_id="O2" value="113.000" spread="11.9762"/>
                    <measurement group_id="O3" value="107.786" spread="12.1919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.200" spread="9.9441"/>
                    <measurement group_id="O2" value="107.467" spread="10.8619"/>
                    <measurement group_id="O3" value="105.500" spread="11.1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.867" spread="10.1620"/>
                    <measurement group_id="O2" value="107.067" spread="6.3860"/>
                    <measurement group_id="O3" value="102.000" spread="12.2725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.067" spread="11.7075"/>
                    <measurement group_id="O2" value="105.933" spread="10.8197"/>
                    <measurement group_id="O3" value="107.429" spread="13.5290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in Blood Pressure</title>
        <description>SBP and DBP were measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Blood Pressure</title>
          <description>SBP and DBP were measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeter of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.756" spread="4.5583"/>
                    <measurement group_id="O2" value="-2.112" spread="5.8242"/>
                    <measurement group_id="O3" value="0.429" spread="6.2950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.823" spread="4.8274"/>
                    <measurement group_id="O2" value="-3.712" spread="7.5868"/>
                    <measurement group_id="O3" value="-0.857" spread="6.0936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.223" spread="5.1037"/>
                    <measurement group_id="O2" value="-1.845" spread="6.6186"/>
                    <measurement group_id="O3" value="0.500" spread="4.4191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.556" spread="4.0795"/>
                    <measurement group_id="O2" value="-2.179" spread="5.8416"/>
                    <measurement group_id="O3" value="-0.857" spread="6.7412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.377" spread="3.8999"/>
                    <measurement group_id="O2" value="0.688" spread="7.8368"/>
                    <measurement group_id="O3" value="1.071" spread="4.3963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.911" spread="6.7287"/>
                    <measurement group_id="O2" value="1.555" spread="7.1028"/>
                    <measurement group_id="O3" value="-0.714" spread="6.2782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.444" spread="4.7072"/>
                    <measurement group_id="O2" value="0.288" spread="6.5408"/>
                    <measurement group_id="O3" value="0.000" spread="6.3519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.644" spread="7.9350"/>
                    <measurement group_id="O2" value="1.088" spread="8.1406"/>
                    <measurement group_id="O3" value="-2.286" spread="4.2171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.644" spread="6.4814"/>
                    <measurement group_id="O2" value="0.821" spread="6.3773"/>
                    <measurement group_id="O3" value="-2.500" spread="7.5579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.156" spread="5.2225"/>
                    <measurement group_id="O2" value="0.111" spread="8.8653"/>
                    <measurement group_id="O3" value="-0.358" spread="7.2826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.289" spread="8.9001"/>
                    <measurement group_id="O2" value="-3.222" spread="11.2680"/>
                    <measurement group_id="O3" value="-0.644" spread="6.9132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.423" spread="7.3588"/>
                    <measurement group_id="O2" value="-2.289" spread="10.0523"/>
                    <measurement group_id="O3" value="-0.144" spread="8.8536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.177" spread="6.2989"/>
                    <measurement group_id="O2" value="-1.355" spread="8.9097"/>
                    <measurement group_id="O3" value="1.356" spread="9.9739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.911" spread="7.8095"/>
                    <measurement group_id="O2" value="2.311" spread="11.0679"/>
                    <measurement group_id="O3" value="-0.858" spread="10.0987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.977" spread="6.7186"/>
                    <measurement group_id="O2" value="4.711" spread="7.4998"/>
                    <measurement group_id="O3" value="0.928" spread="9.8279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.956" spread="7.9095"/>
                    <measurement group_id="O2" value="-0.822" spread="9.2810"/>
                    <measurement group_id="O3" value="-1.358" spread="4.6289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.289" spread="4.9058"/>
                    <measurement group_id="O2" value="-1.222" spread="10.7458"/>
                    <measurement group_id="O3" value="-4.858" spread="9.5294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.089" spread="7.4727"/>
                    <measurement group_id="O2" value="-2.355" spread="9.9198"/>
                    <measurement group_id="O3" value="0.571" spread="11.2671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Pulse Rate at Indicated Time Points</title>
        <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points.</description>
        <time_frame>Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Pulse Rate at Indicated Time Points</title>
          <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY -2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.067" spread="14.6066"/>
                    <measurement group_id="O2" value="62.333" spread="10.8737"/>
                    <measurement group_id="O3" value="60.214" spread="9.4558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.333" spread="10.6212"/>
                    <measurement group_id="O2" value="63.067" spread="7.6108"/>
                    <measurement group_id="O3" value="59.071" spread="10.6516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, PREDOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.023" spread="10.7156"/>
                    <measurement group_id="O2" value="64.311" spread="7.9777"/>
                    <measurement group_id="O3" value="59.857" spread="8.3402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.667" spread="8.5996"/>
                    <measurement group_id="O2" value="72.333" spread="9.2711"/>
                    <measurement group_id="O3" value="58.571" spread="9.3949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.667" spread="11.8301"/>
                    <measurement group_id="O2" value="72.933" spread="9.5877"/>
                    <measurement group_id="O3" value="60.214" spread="10.4010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.133" spread="7.8728"/>
                    <measurement group_id="O2" value="69.467" spread="11.0574"/>
                    <measurement group_id="O3" value="61.214" spread="9.5287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.867" spread="9.9417"/>
                    <measurement group_id="O2" value="68.133" spread="11.0961"/>
                    <measurement group_id="O3" value="66.500" spread="9.4360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.533" spread="10.5144"/>
                    <measurement group_id="O2" value="66.933" spread="7.2552"/>
                    <measurement group_id="O3" value="63.571" spread="10.6027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.867" spread="9.0069"/>
                    <measurement group_id="O2" value="65.867" spread="6.4128"/>
                    <measurement group_id="O3" value="67.143" spread="11.4546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.400" spread="7.1992"/>
                    <measurement group_id="O2" value="61.267" spread="7.6295"/>
                    <measurement group_id="O3" value="64.071" spread="11.5190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.333" spread="6.7259"/>
                    <measurement group_id="O2" value="63.533" spread="6.4572"/>
                    <measurement group_id="O3" value="63.286" spread="10.5278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.267" spread="6.9639"/>
                    <measurement group_id="O2" value="62.467" spread="8.0166"/>
                    <measurement group_id="O3" value="62.286" spread="11.0900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 1, 1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.644" spread="9.2897"/>
                    <measurement group_id="O2" value="8.023" spread="9.3536"/>
                    <measurement group_id="O3" value="-1.286" spread="4.4390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.644" spread="10.5927"/>
                    <measurement group_id="O2" value="8.623" spread="8.8718"/>
                    <measurement group_id="O3" value="0.357" spread="5.2912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.111" spread="7.1157"/>
                    <measurement group_id="O2" value="5.156" spread="10.5863"/>
                    <measurement group_id="O3" value="1.357" spread="4.6853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.844" spread="8.0953"/>
                    <measurement group_id="O2" value="3.823" spread="11.4959"/>
                    <measurement group_id="O3" value="6.643" spread="2.4580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.511" spread="9.0965"/>
                    <measurement group_id="O2" value="2.623" spread="9.1496"/>
                    <measurement group_id="O3" value="3.714" spread="5.1408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 12 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.156" spread="8.6466"/>
                    <measurement group_id="O2" value="1.556" spread="7.3741"/>
                    <measurement group_id="O3" value="7.286" spread="8.0517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.623" spread="8.9894"/>
                    <measurement group_id="O2" value="-3.044" spread="8.7852"/>
                    <measurement group_id="O3" value="4.214" spread="6.3150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.689" spread="8.0818"/>
                    <measurement group_id="O2" value="-0.777" spread="7.8056"/>
                    <measurement group_id="O3" value="3.429" spread="7.7752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.756" spread="9.7834"/>
                    <measurement group_id="O2" value="-1.844" spread="7.4755"/>
                    <measurement group_id="O3" value="2.429" spread="6.6210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Abnormal ECG Findings</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTcF intervals. CS and NCS abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Day -2, Day -1; 1, 2, 4, 6, 8, , 12, 24, 48, 72 hours on Day 1</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Abnormal ECG Findings</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTcF intervals. CS and NCS abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NCS: DAY -2; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY -2; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY -1; n=15, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY -1; n=15, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 1 Hour; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 1 Hour; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 2 Hours; n=15, 15, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 2 Hours; n=15, 15, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 4 Hours; n=15, 13, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 4 Hours; n=15, 13, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 6 Hours; n=14, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 6 Hours; n=14, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 8 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 8 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 12 Hours; n=15, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 12 Hours; n=15, 14, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 24 Hours; n=14, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 24 Hours; n=14, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 48 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 48 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS: DAY 1, 72 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: DAY 1, 72 Hours; n=15, 15, 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in Mean Heart Rate Values as ECG Parameter</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Mean Heart Rate Values as ECG Parameter</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 1, 1 Hour; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.623" spread="3.5038"/>
                    <measurement group_id="O2" value="7.955" spread="7.1040"/>
                    <measurement group_id="O3" value="-0.642" spread="3.6609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 2 Hours; n=15,15,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.623" spread="4.8877"/>
                    <measurement group_id="O2" value="8.489" spread="6.5565"/>
                    <measurement group_id="O3" value="-1.230" spread="4.3393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 4 Hours; n=15,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.156" spread="3.2562"/>
                    <measurement group_id="O2" value="2.500" spread="7.3292"/>
                    <measurement group_id="O3" value="2.144" spread="4.9148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 6 Hours; n=14,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.072" spread="3.0746"/>
                    <measurement group_id="O2" value="1.643" spread="7.5799"/>
                    <measurement group_id="O3" value="5.786" spread="2.6441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 8 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.223" spread="4.5377"/>
                    <measurement group_id="O2" value="1.489" spread="7.0631"/>
                    <measurement group_id="O3" value="2.929" spread="4.3034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 12 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.089" spread="5.0734"/>
                    <measurement group_id="O2" value="-0.178" spread="6.3675"/>
                    <measurement group_id="O3" value="6.072" spread="5.5851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 24 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.377" spread="6.3879"/>
                    <measurement group_id="O2" value="-4.711" spread="7.0854"/>
                    <measurement group_id="O3" value="2.786" spread="4.2971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 48 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.023" spread="7.7608"/>
                    <measurement group_id="O2" value="-2.378" spread="6.3181"/>
                    <measurement group_id="O3" value="2.358" spread="6.3093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 1, 72 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.911" spread="6.1612"/>
                    <measurement group_id="O2" value="-3.045" spread="6.1332"/>
                    <measurement group_id="O3" value="2.286" spread="4.8518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</title>
        <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
        <time_frame>Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters</title>
          <description>Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval; DAY 1, 1 Hour; n= 15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.667" spread="8.7068"/>
                    <measurement group_id="O2" value="-3.067" spread="8.0354"/>
                    <measurement group_id="O3" value="-3.000" spread="4.1236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 2 Hours; n=15,15,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.001" spread="7.7330"/>
                    <measurement group_id="O2" value="-8.000" spread="11.0362"/>
                    <measurement group_id="O3" value="-1.846" spread="6.4305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 4 Hours; n=15,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.067" spread="10.2033"/>
                    <measurement group_id="O2" value="-5.905" spread="8.8947"/>
                    <measurement group_id="O3" value="-2.571" spread="5.2620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 6 Hours; n=14,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.286" spread="8.1501"/>
                    <measurement group_id="O2" value="-4.048" spread="7.9887"/>
                    <measurement group_id="O3" value="-7.286" spread="6.3330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 8 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.267" spread="9.6666"/>
                    <measurement group_id="O2" value="0.267" spread="9.2972"/>
                    <measurement group_id="O3" value="-7.571" spread="5.4017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 12 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.599" spread="7.2967"/>
                    <measurement group_id="O2" value="3.600" spread="10.7074"/>
                    <measurement group_id="O3" value="-5.143" spread="5.5061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 24 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="6.2540"/>
                    <measurement group_id="O2" value="0.667" spread="11.6569"/>
                    <measurement group_id="O3" value="-4.000" spread="5.2761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 48 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533" spread="9.8492"/>
                    <measurement group_id="O2" value="0.267" spread="9.7100"/>
                    <measurement group_id="O3" value="-2.857" spread="4.9369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval; DAY 1, 72 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" spread="6.7270"/>
                    <measurement group_id="O2" value="-0.800" spread="8.3925"/>
                    <measurement group_id="O3" value="0.286" spread="9.5887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 1 Hour; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.177" spread="4.0981"/>
                    <measurement group_id="O2" value="-1.067" spread="2.1485"/>
                    <measurement group_id="O3" value="-1.191" spread="2.1266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 2 Hours; n=15,15,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.289" spread="2.7414"/>
                    <measurement group_id="O2" value="-3.601" spread="5.5916"/>
                    <measurement group_id="O3" value="-1.949" spread="3.6451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 4 Hours; n=15,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.223" spread="4.7522"/>
                    <measurement group_id="O2" value="-3.144" spread="5.5231"/>
                    <measurement group_id="O3" value="-1.334" spread="3.5564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 6 Hours; n=14,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.190" spread="4.4691"/>
                    <measurement group_id="O2" value="-1.096" spread="3.4838"/>
                    <measurement group_id="O3" value="-0.048" spread="2.9515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 8 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.023" spread="5.4315"/>
                    <measurement group_id="O2" value="-1.201" spread="3.2956"/>
                    <measurement group_id="O3" value="-1.476" spread="3.0398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 12 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.577" spread="5.0503"/>
                    <measurement group_id="O2" value="0.266" spread="3.0628"/>
                    <measurement group_id="O3" value="-0.905" spread="2.3614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 24 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.489" spread="3.9399"/>
                    <measurement group_id="O2" value="-0.001" spread="3.2548"/>
                    <measurement group_id="O3" value="-1.762" spread="2.7249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 48 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.489" spread="4.0107"/>
                    <measurement group_id="O2" value="-3.601" spread="5.2408"/>
                    <measurement group_id="O3" value="-2.905" spread="2.8351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval; DAY 1, 72 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.311" spread="3.4718"/>
                    <measurement group_id="O2" value="-1.067" spread="4.7049"/>
                    <measurement group_id="O3" value="-1.905" spread="2.6381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 1 Hour; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.511" spread="9.5694"/>
                    <measurement group_id="O2" value="-23.333" spread="8.8511"/>
                    <measurement group_id="O3" value="-0.334" spread="6.8828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 2 Hours; n=15,15,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.844" spread="12.7773"/>
                    <measurement group_id="O2" value="-26.266" spread="8.5061"/>
                    <measurement group_id="O3" value="1.435" spread="9.3833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 4 Hours; n=15,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.377" spread="12.8317"/>
                    <measurement group_id="O2" value="-15.523" spread="12.6937"/>
                    <measurement group_id="O3" value="-2.191" spread="12.9124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 6 Hours; n=14,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.524" spread="10.6107"/>
                    <measurement group_id="O2" value="-10.619" spread="14.9602"/>
                    <measurement group_id="O3" value="-23.334" spread="16.4029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 8 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.511" spread="12.7754"/>
                    <measurement group_id="O2" value="-6.266" spread="16.7718"/>
                    <measurement group_id="O3" value="-12.762" spread="13.2960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 12 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.044" spread="19.7270"/>
                    <measurement group_id="O2" value="-9.466" spread="15.0727"/>
                    <measurement group_id="O3" value="-24.334" spread="22.8434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 24 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.044" spread="14.0881"/>
                    <measurement group_id="O2" value="0.801" spread="12.2568"/>
                    <measurement group_id="O3" value="-11.476" spread="12.3125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 48 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.644" spread="17.8393"/>
                    <measurement group_id="O2" value="-0.666" spread="14.5496"/>
                    <measurement group_id="O3" value="-7.476" spread="12.3459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval; DAY 1, 72 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.977" spread="15.5657"/>
                    <measurement group_id="O2" value="0.134" spread="13.0685"/>
                    <measurement group_id="O3" value="-12.762" spread="15.3517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 1 Hour; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.666" spread="10.4724"/>
                    <measurement group_id="O2" value="-8.868" spread="7.0866"/>
                    <measurement group_id="O3" value="-2.285" spread="11.8494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 2 Hours; n=15,15,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.133" spread="10.8407"/>
                    <measurement group_id="O2" value="-11.068" spread="8.0958"/>
                    <measurement group_id="O3" value="-2.076" spread="12.2719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 4 Hours; n=15,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.466" spread="10.1552"/>
                    <measurement group_id="O2" value="-11.335" spread="10.1802"/>
                    <measurement group_id="O3" value="1.858" spread="10.9901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 6 Hours; n=14,14,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.714" spread="9.3976"/>
                    <measurement group_id="O2" value="-7.573" spread="12.1949"/>
                    <measurement group_id="O3" value="-10.499" spread="12.0696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 8 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.333" spread="11.3261"/>
                    <measurement group_id="O2" value="-3.268" spread="14.6848"/>
                    <measurement group_id="O3" value="-6.356" spread="11.4959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 12 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.199" spread="11.5629"/>
                    <measurement group_id="O2" value="-9.735" spread="15.8796"/>
                    <measurement group_id="O3" value="-11.214" spread="12.2055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 24 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.933" spread="10.7150"/>
                    <measurement group_id="O2" value="-9.601" spread="9.4605"/>
                    <measurement group_id="O3" value="-5.856" spread="9.6316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 48 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.999" spread="12.4826"/>
                    <measurement group_id="O2" value="-5.601" spread="5.4868"/>
                    <measurement group_id="O3" value="-3.785" spread="9.7479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval; DAY 1, 72 Hours; n=15,15,14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.466" spread="9.5081"/>
                    <measurement group_id="O2" value="-6.401" spread="10.0613"/>
                    <measurement group_id="O3" value="-7.785" spread="12.1949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tlag Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tlag Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.00" upper_limit="3.50"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tmax Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tmax Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.967" lower_limit="1.50" upper_limit="24.02"/>
                    <measurement group_id="O2" value="5.983" lower_limit="2.00" upper_limit="24.03"/>
                    <measurement group_id="O3" value="3.508" lower_limit="2.00" upper_limit="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: T1/2 Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: T1/2 Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.606" spread="14.84"/>
                    <measurement group_id="O2" value="15.692" spread="17.28"/>
                    <measurement group_id="O3" value="17.061" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Tlast Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Tlast Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.983" lower_limit="119.80" upper_limit="120.20"/>
                    <measurement group_id="O2" value="119.983" lower_limit="119.70" upper_limit="120.08"/>
                    <measurement group_id="O3" value="120.017" lower_limit="95.87" upper_limit="120.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Plasma Drug Concentration at 24 Hours (C24) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Drug Concentration at 24 Hours (C24) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.536" spread="41.93"/>
                    <measurement group_id="O2" value="75.643" spread="32.57"/>
                    <measurement group_id="O3" value="26.852" spread="35.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: AUC(0-t) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fasted</title>
            <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: AUC(0-t) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours* nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4595.35" spread="40.28"/>
                    <measurement group_id="O2" value="4371.47" spread="30.03"/>
                    <measurement group_id="O3" value="1776.21" spread="36.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State</title>
        <description>Blood sample were collected at indicated time points to assess pre-dose concentration of GSK2838232 when administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2. Slope and 90 percent confidence interval have been presented.</description>
        <time_frame>Pre-dose on Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10 and Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State</title>
          <description>Blood sample were collected at indicated time points to assess pre-dose concentration of GSK2838232 when administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2. Slope and 90 percent confidence interval have been presented.</description>
          <population>Pharmacokinetic Population</population>
          <units>Nanograms per milliliter per study day</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose, Days 3-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00910" lower_limit="-0.0239" upper_limit="0.00574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 4-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0150" lower_limit="-0.0337" upper_limit="0.00377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 5-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0379" lower_limit="-0.0584" upper_limit="0.0174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 6-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0490" lower_limit="-0.0717" upper_limit="-0.0263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 7-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0679" lower_limit="-0.0971" upper_limit="-0.0388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 8-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0672" lower_limit="-0.111" upper_limit="-0.0233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 9-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.107" lower_limit="-0.182" upper_limit="-0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Days 10-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.263" lower_limit="-0.392" upper_limit="-0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
        <description>Blood sample were collected at indicated time points to calculate accumulation ratio from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, AUC (0-tau) divided by Day 1, AUC (0-tau).</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
          <description>Blood sample were collected at indicated time points to calculate accumulation ratio from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, AUC (0-tau) divided by Day 1, AUC (0-tau).</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3340" spread="0.18272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
        <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Cmax divided by Day 1, Cmax.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
          <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Cmax divided by Day 1, Cmax.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio of Cmax</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2118" spread="0.28582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
        <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Ctau divided by Day 1, Ctau.</description>
        <time_frame>Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
            <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation</title>
          <description>Blood sample were collected at indicated time points to calculate accumulation ratio from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Ctau divided by Day 1, Ctau.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio of Ctau</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3205" spread="0.32907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and Non-SAEs were collected up to 60 days in Part 1 of the study and up to 25 days in Part 2 of the study.</time_frame>
      <desc>SAEs and Non-SAEs were reported for the Safety Population which comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: GSK2838232 200 mg/Ritonavir Capsule Fed</title>
          <description>Participants received a single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: GSK2838232 200 mg/Ritonavir Tablet Fed</title>
          <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 10 mg) tablet formulation along with ritonavir 100 mg tablet administered under fed conditions in treatment periods 1 and 2.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: GSK 200 mg/Ritonavir Tablet Fasted</title>
          <description>Participants received a single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation under fasted conditions in treatment period 3 along with ritonavir 100 mg tablet to be taken with water in fasted condition.</description>
        </group>
        <group group_id="E4">
          <title>Part 2: Placebo</title>
          <description>Eligible participants received single daily doses of placebo tablet orally along with water in fed condition for 11 days.</description>
        </group>
        <group group_id="E5">
          <title>Part 2: GSK2838232 500 mg Tablet Fed</title>
          <description>Eligible participants received non-ritonavir boosted GSK2838232 500 mg, given as single daily doses in fed condition for 11 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03234036
org study id: 205820
nct id: NCT03234036
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This study will be conducted in two Parts to confirm the acceptability/selection of a tablet
      formulation for future clinical development of GSK2838232. Part 1 of the study will assess
      single ritonavir (RTV)-boosted doses of a new tablet formulation given with food (containing
      approximately 30% fat) against the reference capsule formulation also given with food and
      then will assess the impact of fasted conditions on the tablet performance. In Part 2,
      non-boosted GSK2838232 will be given as once-daily tablet doses for 11 days in a separate
      group of subjects, assuming the tablet performance is considered acceptable from Part 1.
      Approximately 16 healthy subjects will be enrolled to provide at least 12 evaluable subjects
      through the three study periods in Part 1. 10 healthy subjects will be enrolled to provide at
      least 8 evaluable subjects through the single study period in Part 2. The maximum duration of
      study participation will be approximately 9 to 10 weeks for Part 1; and 8 to 9 weeks for Part
      2.
allocation: Randomized
intervention model: Crossover Assignment
intervention model description: The randomization number will determine the allocation of treatment sequences (ABC or BAC) for Part 1, and of treatment (GSK2838232 without RTV or placebo) for Part 2. Allocation to treatment for Part 1A or Part 1B (with Part 2 being fixed) will be according to a predetermined random order.
primary purpose: Treatment
masking: Double (Participant, Investigator)
masking description: Part 1 of the study will be open label and thus not be blinded. Part 2 of the study will be single blinded because of the unavailability of matching placebo tablets. The Principal Investigator and the subject will be completely blinded to specific treatment assignment.
measure: Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable [NQ] values were considered as non-missing values).
measure: Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet and capsule formulation in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as tablet formulation in fed and fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
time frame: Up to 25 days
description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Safety Population comprised of all participants who received at least 1 dose of the study treatment (including placebo) with at least 1 post-Baseline safety assessment. Number of participants with SAEs and common non-SAEs (>=5%) are presented.
measure: Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria
time frame: Up to 25 days
description: Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were < 0.075 or >0.54 proportion of red blood cells in blood for hematocrit, <25 or >180 grams per liter (g/L) for hemoglobin, < 3 or >20 cells per liter (cells/L) for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and <100 or >550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.
measure: Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria
time frame: Up to 25 days
description: Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, calcium, potassium and sodium. PCI ranges were <30 g/L for albumin, <2 or >2.75 millimoles per liter (mmol/L) for calcium, <3 or >9 mmol/L for glucose, >=2 times Upper limit of Normal (ULN) units per liter (U/L) for ALT, >=2 times ULN U/L for alkaline phosphatase, >=2 times ULN U/L for AST, >=1.5 times ULN micromoles per liter (µmol/L) for bilirubin, <3 or >5.5 mmol/L for potassium, and <130 or >150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.
measure: Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria
time frame: Up to 25 days
description: Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, potential of hydrogen (pH), presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the "To Normal or No Change" category.
measure: Part 2: Blood Pressure at Indicated Time Points
time frame: Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)
description: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in supine position after 10 minutes rest for the participants at indicated time points.
measure: Part 2: Change From Baseline in Blood Pressure
time frame: Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)
description: SBP and DBP were measured in supine position after 10 minutes rest for participants at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 2: Pulse Rate at Indicated Time Points
time frame: Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)
description: Pulse rate of participants was measured in supine position after 10 minutes rest at indicated time points.
measure: Part 2: Change From Baseline in Pulse Rate
time frame: Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)
description: Pulse rate was measured in supine position after 10 minutes rest at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 2: Number of Participants With Abnormal Electrocardiogram (ECG) Findings
time frame: Day -1; 1, 4, 12 hours on Day 1; Days 2, 3, 5, 8; 1, 4, 12, 24 Hours on Day 11; Follow-up (Day 25)
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
measure: Part 2: Change From Baseline in Mean Heart Rate Values as ECG Parameter
time frame: Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 2: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters
time frame: Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as a non-boosted once-daily dosing tablet in fed state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Number of Participants With SAEs and Non-SAEs
time frame: Up to 60 days
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect, is associated with liver injury or impaired liver function or any other situations as per medical or scientific judgment. Number of participants with SAEs and common non-SAEs (>=5%) are presented.
measure: Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria
time frame: Up to 60 days
description: Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were >0.54 as proportion of red blood cells in blood for hematocrit, >180 g/L for hemoglobin, < 3 or >20 cells/L for leukocytes, 0.8 x10^9 cells/L for lymphocytes, 1.5 x10^9 cells/L for neutrophils, and <100 or >550 cells/L for platelets. Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.
measure: Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria
time frame: Up to 60 days
description: Blood samples were collected from participants for analysis of following clinical chemistry parameters; glucose, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium, potassium and sodium. PCI ranges were <30 g/L for albumin, <2 or 2.75 mmol/L for calcium, <3 or >9 mmol/L for glucose, >=2 times ULN U/L for ALT, >=2 times ULN U/L for alkaline phosphatase, >=2 times ULN U/L for AST, >=1.5 times ULN µmol/L for bilirubin, <3 or >5.5 mmol/L for potassium, and <130 or >150 mmol/L for sodium. Participants were counted in the worst case category that their value changes to (low, within range or no change,or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "To within Range or No Change" category.
measure: Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria
time frame: Up to 60 days
description: Urine samples were collected from participants for analysis of following urinalysis parameters; specific gravity, pH, presence of glucose, protein, occult blood, ketones in urine analyzed by dipstick method. The dipstick test gives results in a semi-quantitative manner. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The reference range is 1.002-1.030. Urine pH is an acid-base measurement. Normal urine has a slightly acid pH (5.0 - 6.0). Participants were counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became normal, were recorded in the "To Normal or No Change" category.
measure: Part 1: Blood Pressure at Indicated Time Points
time frame: Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1
description: SBP and DBP of participants were measured in supine position after 10 minutes rest at indicated time points.
measure: Part 1: Change From Baseline in Blood Pressure
time frame: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1
description: SBP and DBP were measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 1: Pulse Rate at Indicated Time Points
time frame: Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1
description: Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points.
measure: Part 1: Change From Baseline in Pulse Rate
time frame: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1
description: Pulse rate was measured in supine position after 10 minutes rest for the participant at indicated time points. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 1: Number of Participants With Abnormal ECG Findings
time frame: Day -2, Day -1; 1, 2, 4, 6, 8, , 12, 24, 48, 72 hours on Day 1
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTcF intervals. CS and NCS abnormal ECG findings have been presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
measure: Part 1: Change From Baseline in Mean Heart Rate Values as ECG Parameter
time frame: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates the heart rate. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 1: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters
time frame: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1
description: Single and triplicate 12-lead ECG's were obtained at least 5 minutes apart in the supine position after 10 minutes of rest at indicated time points using an ECG machine that automatically calculates measures PR, QRS, QT and QTcF intervals. Baseline was defined as the latest pre-dose assessment, including those from unscheduled visits. Change from Baseline was defined as any visit value minus Baseline value.
measure: Part 1: Tlag Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Tlag is a time delay between drug administration and first observed concentration. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Tmax Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: T1/2 Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Tlast Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: Plasma Drug Concentration at 24 Hours (C24) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 1: AUC(0-t) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State
time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1
description: Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232 given as capsule and tablet formulation in fed state as well as tablet formulation in fasted state. Pharmacokinetic parameters were determined using standard non-compartmental methods.
measure: Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State
time frame: Pre-dose on Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10 and Day 11 in Part 2
description: Blood sample were collected at indicated time points to assess pre-dose concentration of GSK2838232 when administered as non-boosted once-daily doses of a tablet formulation for 11 days in Part 2. Slope and 90 percent confidence interval have been presented.
measure: Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood sample were collected at indicated time points to calculate accumulation ratio from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, AUC (0-tau) divided by Day 1, AUC (0-tau).
measure: Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood sample were collected at indicated time points to calculate accumulation ratio from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Cmax divided by Day 1, Cmax.
measure: Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation
time frame: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2
description: Blood sample were collected at indicated time points to calculate accumulation ratio from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation. Accumulation ratio of GSK2838232 was evaluated by Day 11, Ctau divided by Day 1, Ctau.
arm group label: Treatment sequence ABC: Part 1
arm group type: Experimental
description: A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.
Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
There will be a wash out of 15 days between Part 1A and Part 1B.
arm group label: Treatment sequence BAC: Part 1
arm group type: Experimental
description: A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.
A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.
A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
There will be a wash out of 15 days between Part 1A and Part 1B.
arm group label: GSK2838232 tablet without RTV: Part 2
arm group type: Experimental
description: In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
arm group label: Placebo without RTV: Part 2
arm group type: Placebo Comparator
description: In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
intervention type: Drug
intervention name: GSK2838232 100 mg tablet
description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
arm group label: GSK2838232 tablet without RTV: Part 2
arm group label: Treatment sequence ABC: Part 1
arm group label: Treatment sequence BAC: Part 1
intervention type: Drug
intervention name: GSK2838232 50 mg capsule
description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
arm group label: Treatment sequence ABC: Part 1
arm group label: Treatment sequence BAC: Part 1
intervention type: Drug
intervention name: Ritonavir 100 mg tablets
description: It is a white film-coated ovaloid tablets.
arm group label: Treatment sequence ABC: Part 1
arm group label: Treatment sequence BAC: Part 1
intervention type: Drug
intervention name: Placebo for GSK2838232 tablets
description: It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
arm group label: Placebo without RTV: Part 2
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United States
citation: Johnson M, Jewell RC, Gan J, Dumont E, Burns O, Johns BA. A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses. Clin Pharmacol Drug Dev. 2020 Nov;9(8):972-977. doi: 10.1002/cpdd.820. Epub 2020 Jun 18.
PMID: 32558338
responsible party type: Sponsor
mesh term: Infections
mesh term: Communicable Diseases
mesh term: HIV Infections
mesh term: Acquired Immunodeficiency Syndrome
mesh term: Ritonavir
mesh term: GSK-2838232
sharing ipd: Yes
ipd description: IPD for this study is available via the Clinical Study Data Request site.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
ipd access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
ipd url: https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20589
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 